Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ODTX · NASDAQ · Biological Products, (No Diagnostic Substances) · No 10-K yet
Odyssey Therapeutics (ODTX) · oqro.io/stocks/ODTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$19.14−0.96 (−4.78%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Fund moves
4 tracked managers disclosed the same change for Q2 2026. Among this manager's largest new positions for Q2 2026.
Fund moves
4 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Institutions reporting a stake, Q2 2026
58
$651M reported in total
Share of stock reported
72.4%
34.8M of 48.1M shares outstanding
Change vs Q1 2026
+34.8M shares
58 new positions, 0 positions closed
Reported in 13F filings, which cover managers over $100M and include double counting. A 13F shows holdings on the last day of the quarter, not when shares were bought or sold. Change counts the 58 managers that reported both quarters.
Source: SEC Form 13F data sets, every filer, common stock only (options and bonds left out). Amendments are applied; lines whose value was filed in thousands are scaled, and lines whose shares and value disagree are left out.
